At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Ari Hakimi, Associate Professor and Urologic Surgeon at Memorial Sloan Kettering Cancer Center, delivered a talk on “Modern Prognostic Models for Localized RCC”.
Dr. Hakimi reviewed established tools such as the UISS and SSIGN models, along with more contemporary nomograms, noting that while they remain widely referenced, none have yet reached routine clinical use. He emphasized their limitations in predictive accuracy, especially when tested prospectively, but also discussed how these models still guide risk stratification in research and patient counseling.
He further highlighted efforts to integrate biomarkers and molecular signatures into prognostic models, aiming to improve their ability to identify patients at higher risk and personalize management strategies for localized RCC.
Join us in this conversation.